Skip to main content
. 2021 Mar 3;3:644319. doi: 10.3389/fgeed.2021.644319

Figure 2.

Figure 2

CRISPR/Cas9 delivery platforms and routes of administration. A list of advantages (green) and drawbacks (red) of viral (lentiviral and adeno-associated vectors) and non-viral (nanoparticles) delivery methods. Troubleshooting methods (blue) to overcome potential drawbacks are reported. The delivery routes of viral vectors and nanoparticles are indicated, highlighting their advantages (green) and limitations (red). IP, intraparenchymal; ICV, intracerebroventricular; IT, intrathecal; IV, intravenous; CRISPR, clustered regularly interspaced short palindromic repeats.